Please assess the completion status of the following clinical trial:

Trial Title: DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic renal cell carcinoma with measurable disease.~* Tumor tissue available and properly stored for lysate preparation.~* Patients must be at least 4 weeks from their last immunotherapy, radiation, surgery or chemotherapy (6 weeks for nitrosureas) and recovered from all ill effects.~* Karnofsky Performance Status ≥60%~* Life expectancy ≥ twelve weeks~* Adequate end organ function:~* Hematological: ANC ≥ 1000cells/μL, platelets ≥ 75,000/μL, hemoglobin ≥ 8.5 g/dl~* Liver: AST \< 2 x ULN (upper limit of normal) unless due to metastases then \< 5 x ULN, serum total bilirubin \< 2 x ULN (except for patients with Gilbert's Syndrome)~* Renal: serum creatinine \< 2.0 x ULN.~* Pulmonary: FEV1 \> 2.0 liters or \> 75% of predicted for height and age.~* Cardiac: No evidence of congestive heart failure, symptoms of coronary artery disease, myocardial infarction less than 6 months prior to entry, or serious cardiac arrhythmias. Patients over 40 or have had previous myocardial infarction greater than 6 months prior to entry will be required to have a negative or low probability cardiac stress test for cardiac ischemia.~* CNS: No history of brain metastases.~* Women should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the study.~* Appropriate Contraception in both sexes~EXCLUSION CRITERIA:~* Patients may have not have been treated previously with IL-2, IFNα or autologous vaccine.~* Concomitant second malignancy except for non-melanoma skin cancer, and non- invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence, breast CIS.~* In patients with a prior history of invasive malignancy, less than five years in complete remission~* Positive serology for HIV, hepatitis B or hepatitis C,~* Significant co-morbid illness such as uncontrolled diabetes or active infection that would preclude treatment on this regimen.~* Use of corticosteroids or other immunosuppression (if patient had been taking steroids, at least 4 weeks must have passed since the last dose).~* History of autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine, Aldesleukin-2, Interferon-a (Type: EXPERIMENTAL): All patients will be treated with autologous tumor cell vaccine administered into inguinal lymph nodes via ultrasound guidance in addition to systemic IL-2 and recombinant interferon alfa. Two cycles of induction IL-2/IFNα-2a followed by 3 cycles of maintenance IL-2 + IFNα-2a.

Based on this trial design, predict the completion outcome and termination type (if applicable).